美国阿兹海默症诊断影像市场规模、份额和趋势分析报告：按诊断影像方式、最终用途和细分市场预测（2025-2033 年）

市场规模与趋势：

2024 年美国阿兹海默症相关影像诊断市场规模估计为 44.9 亿美元，预计到 2033 年将达到 69 亿美元。

预计2025年至2033年复合年增长率将达5.1%。市场成长的主要驱动因素是美国阿兹海默症症患者人数的不断增加。根据美国国家医学图书馆（NLH）2024年的数据，目前约有690万65岁及以上的美国患有老年痴呆症失智症，如果到2060年没有突破性治疗方法问世，这一数字可能达到1380万。阿兹海默症目前是美国老年人第五大死因，显示其对公共卫生的影响日益加剧。

随着阿兹海默症患者病率的上升，对早期诊断和持续监测的需求也日益增长。这为阿兹海默症症影像技术和服务领域的投资与创新创造了巨大的机会。各国政府和公共卫生机构也积极支持这一趋势。例如，美国疾病管制与预防中心（CDC）的阿兹海默症计画致力于提高公众意识、促进早期发现并提升诊断能力。这些努力共同推动了美国诊断基础设施的扩建、影像服务的可及性提升以及脑部疾病影像技术的进步。

此外，拉什大学的一项研究发现，美国阿兹海默症率有显着的区域差异，佛罗里达州和马里兰州等州的盛行率最高。这些县级差异受多种因素影响，例如人口年龄分布、社会经济经济状况、医疗保健资源以及生活方式习惯。

在美国，技术创新持续推动阿兹海默症影像产业的成长。目前，磁振造影（MRI）、正子断层扫描（PET）和单光子发射电脑断层扫描（SPECT）等技术是诊断和后续观察阿兹海默症的重要工具。 MRI 可提供清晰的解剖影像，PET 可视觉化和量化β-淀粉样蛋白斑块和Tau蛋白纤维缠结，而 SPECT 则用于评估脑血流和功能障碍。这些技术在美国各地的医院和门诊影像中心被广泛用于诊断和治疗方案製定。

人工智慧辅助诊断技术正在改变美国阿兹海默症诊断影像市场。例如，梅奥诊所的StateViewer人工智慧系统仅需一次氟代脱氧葡萄糖正子断层扫描（FDG-PET）即可检测出包括阿兹海默症在内的九种失智症。透过提高诊断准确率和缩短解读时间，人工智慧正在扩大先进诊断技术的普及范围，并增强临床医生对早期准确诊断的信心。

此外，该市场拥有强而有力的政府支持和战略规划。例如，隶属于美国卫生与公众服务部的国家老龄研究所 (NIA)统筹所有联邦政府应对阿兹海默症(AD) 及相关失智症的活动。由《国家阿兹海默阿兹海默症行动法案》(NAPA) 设立的《国家阿兹海默症症计画》旨在加速研究和治疗，并在许多相关领域加强对患者、家属和看护者的支持。该计划的主要重点是改善早期检测、提升患者照护和看护者体验、推广有效的护理模式，以及推进诊断和治疗方面的研究。这些措施体现了美国政府致力于加强阿兹海默症护理基础设施和研究能力、促进先进诊断和影像技术的应用，以及支持阿兹海默症症影像市场发展的决心。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国阿兹海默症影像诊断市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关及附随市场展望
• 市场动态
• 美国阿兹海默症相关影像诊断市场分析工具
  • 产业分析：波特五力模型
  • PESTEL 分析

第四章美国阿兹海默症诊断影像市场：诊断影像方式的估计与趋势分析

• 美国阿兹海默症诊断影像市场：诊断影像方式变化分析
• 美国阿兹海默症诊断影像市场：按诊断成像方式分類的展望
• 市场规模、预测与趋势分析（2021-2033）
• 正子断层扫描（PET）
  • 淀粉样蛋白正子断层扫描（PET）
  • Tau正子断层扫描
  • FDG正子断层扫描
• 磁振造影（MRI）
  • 结构性磁振造影（MRI）
  • 高阶磁振造影（MRI）
• 单光子发射电脑断层扫描（SPECT）
• 其他的

第五章美国阿兹海默症诊断影像市场：终端用户估算与趋势分析

• 美国老年痴呆症诊断影像市场：终端用途差异分析
• 美国老年痴呆症诊断影像市场：按最终用途分類的展望
• 市场规模、预测与趋势分析（2021-2033）
• 医院和诊所
• 诊断影像中心
• 受託研究机构（CRO）
• 其他的

第六章 竞争情势

• 市场参与企业分类
• 主要企业简介
  • GE Healthcare
  • Siemens Healthineers AG
  • Life Molecular Imaging（LMI）
  • Eli Lilly and Company
  • SOFIE Biosciences
  • Lantheus Holdings, Inc.
  • Jubilant Radiopharma
  • Brainreader A/S/Neuroreader
  • Koninklijke Philips NV
  • Alzevita

Market Size & Trends:

The U.S. Alzheimer's-linked imaging market size was estimated at USD 4.49 billion in 2024 and is projected to reach USD 6.90 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. Market growth is mainly driven by the rising number of Alzheimer's cases across the country. According to the National Library of Medicine (NLH) (2024), around 6.9 million Americans aged 65 and older are currently living with Alzheimer's dementia, and this number could reach 13.8 million by 2060 if no breakthrough occurs. Alzheimer's is now the fifth-leading cause of death among older adults in the U.S., highlighting its growing public health impact.

As the prevalence of the disease increases, demand for early diagnosis and continuous monitoring is rising. This is creating strong opportunities for investment and innovation in Alzheimer's-related imaging technologies and services. Government and public health agencies are also supporting this trend. For instance, the Centers for Disease Control and Prevention's (CDC) Alzheimer's disease Program promotes awareness, early detection, and diagnostic readiness. Together, these initiatives are helping expand diagnostic infrastructure, improve access to imaging services, and encourage technological advancements in brain-disease imaging across the U.S.

Furthermore, a study by Rush University highlighted significant regional differences in Alzheimer's disease prevalence across the U.S., with the highest rates observed in states such as Florida and Maryland. These county-level variations are influenced by factors such as population age distribution, socioeconomic conditions, healthcare accessibility, and lifestyle habits.

Technological advancements continue to drive the growth of the U.S. Alzheimer's-linked imaging industry. Currently used techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential methods for the diagnosis and monitoring of Alzheimer's disease. MRI provides excellent anatomical imaging, PET allows visualization and quantification of amyloid-B plaques and tau tangles, and SPECT assesses cerebral blood flow and deficits in brain function. These techniques are routinely used to plan diagnosis and treatment in hospitals and outpatient imaging centers throughout the U.S.

AI-assisted diagnostics are transforming the U.S. Alzheimer's-linked imaging market. For instance, Mayo Clinic's StateViewer AI can detect nine types of dementia, including Alzheimer's, from a single fluorodeoxyglucose positron emission tomography (FDG-PET) scan. By enhancing accuracy and reducing interpretation time, AI expands access to advanced diagnostics and boosts confidence in early, precise detection across clinical settings.

Furthermore, strong governmental support and strategic planning exist within the market. For instance, the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, oversees all federal activities aimed at addressing Alzheimer's disease (AD) and related dementias. The National Alzheimer's Project Act (NAPA) established the National Plan to Address Alzheimer's Disease, which aims to accelerate research, treatment, and support patients, families, and caregivers on various related topics. The plan's primary focus is on improving early detection, enhancing patient care and the caregiver experience, expanding effective care models, and advancing research in diagnosis and treatment. These initiatives reflect the U.S. government's commitment to strengthening Alzheimer's care infrastructure and research capacity, fostering wider adoption of advanced diagnostic and imaging technologies, and supporting growth in the Alzheimer's-linked imaging market.

U.S. Alzheimer's-linked Imaging Market Report Segmentation

This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Alzheimer's-linked imaging market report based on imaging modality, and end use:

• Imaging Modality Outlook (Revenue, USD Million, 2021 - 2033)
• Positron Emission Tomography
  • Amyloid Positron Emission Tomography
  • Tau Positron Emission Tomography
  • FDG- Positron Emission Tomography
• Magnetic Resonance Imaging
  • Structural Magnetic Resonance Imaging
  • Advanced Magnetic Resonance Imaging
• Single Photon Emission Computed Tomography
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Imaging Centers
• Contract Research Organizations (CROs)
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Imaging Modality
  • 1.2.2. End Use
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Imaging Modality Outlook
  • 2.2.2. End Use Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Alzheimer's-linked Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of Alzheimer's disease
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Governmental support and strategic planning
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Equipment Costs
    • 3.2.2.2. Limited Accessibility
• 3.3. U.S. Alzheimer's-linked Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. U.S. Alzheimer's-linked Imaging Market: Imaging Modality Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Alzheimer-linked Imaging Market: Imaging Modality Movement Analysis
• 4.3. U.S. Alzheimer-linked Imaging Market by Imaging Modality Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Positron Emission Tomography
  • 4.5.1. Positron Emission Tomography Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Amyloid Positron Emission Tomography (PET)
    • 4.5.2.1. Amyloid Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Tau Positron Emission Tomography
    • 4.5.3.1. Tau Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. FDG- Positron Emission Tomography
    • 4.5.4.1. FDG-Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Magnetic Resonance Imaging (MRI)
  • 4.6.1. Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Structural Magnetic Resonance Imaging (MRI)
    • 4.6.2.1. Structural Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Advanced Magnetic Resonance Imaging (MRI)
    • 4.6.3.1. Advanced Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Single Photon Emission Computed Tomography (SPECT)
  • 4.7.1. Single Photon Emission Computed Tomography (SPECT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Alzheimer's-linked Imaging Market: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Alzheimer-linked Imaging Market: End Use Movement Analysis
• 5.3. U.S. Alzheimer-linked Imaging Market by End Use Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Hospitals & Clinics
  • 5.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Diagnostic Imaging Centers
  • 5.6.1. Diagnostic Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Contract Research Organizations (CROs)
  • 5.7.1. Contract Research Organizations (CROs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. GE Healthcare
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic initiatives
  • 6.2.2. Siemens Healthineers AG
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. Life Molecular Imaging (LMI)
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Eli Lilly and Company
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. SOFIE Biosciences
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives
  • 6.2.6. Lantheus Holdings, Inc.
    • 6.2.6.1. Company overview
    • 6.2.6.2. Financial performance
    • 6.2.6.3. Product benchmarking
    • 6.2.6.4. Strategic initiatives
  • 6.2.7. Jubilant Radiopharma
    • 6.2.7.1. Company overview
    • 6.2.7.2. Financial performance
    • 6.2.7.3. Product benchmarking
    • 6.2.7.4. Strategic initiatives
  • 6.2.8. Brainreader A/S/ Neuroreader
    • 6.2.8.1. Company overview
    • 6.2.8.2. Financial performance
    • 6.2.8.3. Product benchmarking
    • 6.2.8.4. Strategic initiatives
  • 6.2.9. Koninklijke Philips N.V.
    • 6.2.9.1. Company overview
    • 6.2.9.2. Financial performance
    • 6.2.9.3. Product benchmarking
    • 6.2.9.4. Strategic initiatives
  • 6.2.10. Alzevita
    • 6.2.10.1. Company overview
    • 6.2.10.2. Financial performance
    • 6.2.10.3. Product benchmarking
    • 6.2.10.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Alzheimer's-linked imaging market, by imaging modality, 2021 - 2033 (USD Million)
• Table 4 U.S. Alzheimer's-linked imaging market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 U.S. Alzheimer's-linked imaging: market outlook
• Fig. 9 U.S. Alzheimer's-linked imaging market competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 U.S. Alzheimer's-linked imaging market driver impact
• Fig. 15 U.S. Alzheimer's-linked imaging market restraint impact
• Fig. 16 U.S. Alzheimer's-linked imaging market strategic initiatives analysis
• Fig. 17 U.S. Alzheimer's-linked imaging market: imaging modality movement analysis
• Fig. 18 U.S. Alzheimer's-linked imaging market: imaging modality outlook and key takeaways
• Fig. 19 Positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 20 Amyloid positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 21 Tau positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 22 FDG- positron emission tomography (PET) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 23 Magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 24 Structural magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 25 Advanced magnetic resonance imaging (MRI) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 26 Single photon emission computed tomography (SPECT) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 27 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 28 U.S. Alzheimer's-linked imaging market, end use outlook key takeaways (USD Million)
• Fig. 29 U.S. Alzheimer's-linked imaging market end use movement analysis (USD Million), 2024 & 2033
• Fig. 30 Hospitals & clinics market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 31 Diagnostic imaging centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 32 Contract research organizations (CROs) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 33 Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 34 Participant categorization- U.S. Alzheimer's-linked imaging market
• Fig. 35 Market share of key market players- U.S. Alzheimer's-linked imaging market